Searched for
EUROPE CIPLA
These large-, mid- and small-cap stocks can give more than 25% return in 1 year, according to analysts- These large- mid- and small-cap stocks can give more than 25% return in 1 year, according to analysts
- Sweet pills: How pharma stocks delivered bumper returns to Indian investors, defying 2026 whiplash
- AI video startup TrueFan raises $10 million led by Baring PE, Z3PartnersGurugram's TrueFan AI secured $10 million, valuing it at $40 million, to fuel its AI-generated video platform. Serving over 100 enterprises...04 Jun, 2026, 12.04 PM IST
- Zaynich's blockbuster potential lifts Wockhardt's long-term outlookWockhardt's novel antibiotic, Zaynich, has received USFDA approval after a 12-year effort, sparking hopes for a turnaround after years of n...02 Jun, 2026, 05.48 AM IST
- Cipla is aiming for 40-50 global product filings in three years, says MD Achin GuptaCipla is charting its next growth phase with a strong focus on innovation, complex generics, and biosimilars. The company plans significant...29 May, 2026, 05.30 AM IST
- Innovation, biosimilars, complex generics to drive Cipla's growth: Achin Gupta, MD & Group CEOAs Cipla approaches its centenary, the company is redefining its strategy by prioritizing innovation to amplify revenues. With ambitions to...29 May, 2026, 12.57 AM IST
- Tata-backed MedTherapy claims CAR-T breakthrough with one-day productionTata Sons-backed biotech startup MedTherapy said it has developed a next-generation CAR-T cell therapy manufacturing platform that can redu...27 May, 2026, 08.27 PM IST
- Cipla Q4 Results: Profit falls 55% YoY to Rs 555 crore; co declares Rs 13/sh dividendCipla Ltd announced a significant 55% year-on-year drop in its consolidated net profit for the fourth quarter, reaching Rs 555 crore. This ...13 May, 2026, 01.18 PM IST
- Pharma Q4 outlook mixed: Hospitals steady, generics face revlimid dragIndian pharma and healthcare firms face a mixed March quarter. While hospitals anticipate steady growth, generic drugmakers grapple with lo...04 May, 2026, 06.00 AM IST
- What we had done for India, we are now doing for US: Umang Vohra, MD, CiplaIn an interview with Suman Layak, Vohra explains his strategy of taking Cipla products to global markets.04 May, 2019, 11.00 PM IST
- Cipla ties up with Serum Institute to sell vaccines in South AfricaCipla said it had agreed to an exclusive deal with Serum Institute to supply vaccines to South Africa, adding a new market to their partner...08 Oct, 2015, 03.48 PM IST
- Stempeutics gets EMA approval to market stem cell drug in EUThe ATMP classification, approved by the committee for Advanced Therapies (CAT) of the EMA will allow the Bengaluru- based Stempeutics to c...23 Mar, 2015, 03.17 PM IST
- Cipla shares end nearly 4% higher post agreement with Serum InstituteCipla's stock surged 3.23 per cent to settle at Rs 618.60 on the BSE. In intra-day, it climbed 4.13 per cent to Rs 624.20 Nov, 2014, 06.13 PM IST
- Cipla Ltd to market Serum Institute's paediatric vaccines in EuropeCipla has launched multiple respiratory products in Europe this year, and launch of some key inhalers is expected in 2015.20 Nov, 2014, 12.53 PM IST
- Cipla announces commercial tie-up with UK's S&D PharmaPharmaceutical firm Cipla today announced commercial collaboration with UK-based S&D Pharma in the Czech Republic and Slovakia.08 Sep, 2014, 04.42 PM IST
- Cipla launches combination inhalers in Germany and Sweeden; stocks touch all time high, may trigger reratingThe maiden launch increases the possibility and visibility of subsequent launches of the company’s inhalers in other countries.04 Sep, 2014, 03.32 AM IST
- Cipla, BioQuiddity ink pact to sell pain management productCipla intends to launch the CE marked OneDose ReadyfusOR pre-filled with Ropivacaine under its own label into the German market late this y...31 Jul, 2014, 02.11 PM IST
- Cipla floats in-house venture capital firmCipla's new initiative comes at a time when the company is making bold moves in expanding its international business.21 Jun, 2013, 04.46 AM IST
- Ex-Teva Frank Pieters to lead Cipla's European respiratory businessCipla, India's second-largest drug maker, has hired Teva's former vice-president Frank Pieters to spearhead its European respiratory busine...04 Jul, 2012, 05.05 AM IST
Load More
